<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303429</url>
  </required_header>
  <id_info>
    <org_study_id>IMCC</org_study_id>
    <nct_id>NCT04303429</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy in High Risk Stage II Colon Cancer</brief_title>
  <official_title>Adjuvant Chemotherapy Versus Observation in Stage II Colon Cancer Patients With High-Risk Factors and High-Immunoscore®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Benefit of adjuvant chemotherapy after curative surgery for stage II Colon Cancer is
           still debated. Several high-risk features may help to stratify stage II cancer patients
           into groups that will truly benefit from adjuvant chemotherapy. However, those factors
           are rather subjective, and no specific trial has been designed to answer the high-risk
           stage II colon cancer question directly.

        -  Immunoscore® Colon, an in vitro diagnostic test, which quantifies the density of CD3+
           and CD8+ T lymphocyte populations in the center the tumor (CT) and its invasive margin
           (IM) using immunohistochemistry and automated image analysis. Immunoscore® has been
           extensively validated as a prognostic biomarker in early stage CC patients. This unique
           diagnostic assay measuring host immune response at the tumor site may inform the
           decision to administer adjuvant chemotherapy in resected Stage II and III CC patients.

        -  This randomized trial is studying how observation compares to adjuvant chemotherapy
           (investigator's choice) in stage II colon cancer patients with high-risk features and
           High-Immunoscore®. The trial would represent a unique opportunity to classify stage II
           CC patients based on their tumor microenvironment with the aim to provide efficient
           patient stratification to improve clinical care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the noninferiority of observation as compared to standard of care adjuvant chemotherapy (investigator's choice) in patients with high-risk stage II CC and High-Immunoscore® in terms of disease free survival (DFS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence (TTR)</measure>
    <time_frame>From date of enrollment until the date of recurrence,assessed 1year,3years and 5years after therapy</time_frame>
    <description>To evaluate the noninferiority of observation as compared to standard of care adjuvant chemotherapy (investigator's choice) in patients with high-risk stage II CC and High-Immunoscore® in terms of Time To Recurrence (TTR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of enrollment until the date of death,assessed 1year,3years and 5years after therapy</time_frame>
    <description>To evaluate the noninferiority of observation as compared to standard of care adjuvant chemotherapy (investigator's choice) in patients with high-risk stage II CC and High-Immunoscore® in terms of overall survival (OS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost Utility Analysis</measure>
    <time_frame>through study completion,an average of 3 years</time_frame>
    <description>An cost utility analysis at the country level will be conducted alongside the clinical evaluation (exploratory)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">962</enrollment>
  <condition>Stage II Colon Cancer</condition>
  <condition>Adjuvant Chemotherapy</condition>
  <arm_group>
    <arm_group_label>observation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients enrolled in the observation group will not receive any chemotherapy drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX/XELOX/Capecitabine</intervention_name>
    <description>Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.</description>
    <arm_group_label>adjuvant chemotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years old

          2. Pathologically confirmed adenocarcinoma of the colon

          3. Complete resection of the primary tumor without gross or microscopic evidence of
             residual disease

          4. Histologically proven stage II: T3-T4 N0

          5. At least one of the following factors:T4 staging,Number of examined lymph nodes &lt;
             12,poor differentiation (except MSI-H),LVI or PNI,tumor perforation or occlusion

          6. Treatment within 7 weeks following surgery

          7. ECOG PS 0-1

          8. No prior chemo, immuno or radiotherapy

          9. Patients must read, agree to, and sign a statement of Informed Consent prior to
             participation in this study.

        Exclusion criteria

          1. Have a birth plan during the clinical trial;

          2. Severe cardiovascular diseases such as cerebrovascular accidents occurring within 6
             months, myocardial infarction, hypertension that cannot be controlled after drug
             intervention, unstable angina pectoris, heart failure (NYHA 2-4), and arrhythmia
             requiring drugs Intervention;

          3. Dementia, mental state changes or any mental illness that may interfere with
             understanding or making informed consent or completing a questionnaire;

          4. Subjects with ≥1 peripheral neuropathy according to CTCAE V version 4.03;

          5. Allergy or hypersensitivity history of the drug or drug ingredient used in this test;

          6. Excluding other malignant tumors, cured basal cell carcinoma of the skin or squamous
             cell carcinoma of the skin or any other part of the carcinoma in situ;

          7. Have received any other test drug treatment or participated in another interventional
             clinical trial within 30 days of the screening period;

          8. The investigator believes that it is not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>qi li, MD,PhD</last_name>
    <phone>+8613818207333</phone>
    <email>Leeqi2001@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haiyan Zhang, MD</last_name>
    <phone>+8613611956117</phone>
    <email>Zhymmx@sina.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29;313(5795):1960-4.</citation>
    <PMID>17008531</PMID>
  </reference>
  <reference>
    <citation>Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009 Dec 10;27(35):5944-51. doi: 10.1200/JCO.2008.19.6147. Epub 2009 Oct 26.</citation>
    <PMID>19858404</PMID>
  </reference>
  <reference>
    <citation>Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011 Feb 20;29(6):610-8. doi: 10.1200/JCO.2010.30.5425. Epub 2011 Jan 18.</citation>
    <PMID>21245428</PMID>
  </reference>
  <reference>
    <citation>Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, Fredriksen T, Mauger S, Waldner M, Berger A, Speicher MR, Pagès F, Valge-Archer V, Galon J. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016 Feb 24;8(327):327ra26. doi: 10.1126/scitranslmed.aad6352.</citation>
    <PMID>26912905</PMID>
  </reference>
  <reference>
    <citation>Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Mauillon J, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Michel P, Sesboüe R, Frebourg T, Pagès F, Valge-Archer V, Latouche JB, Galon J. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity. 2016 Mar 15;44(3):698-711. doi: 10.1016/j.immuni.2016.02.025.</citation>
    <PMID>26982367</PMID>
  </reference>
  <reference>
    <citation>Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.</citation>
    <PMID>29754777</PMID>
  </reference>
  <reference>
    <citation>Sinicrope F et al. Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). J Clin Oncol 36, 2018 (suppl 4S; abstr 614)</citation>
  </reference>
  <reference>
    <citation>Galon J, Hermitte F, Mlecnik B, et al. Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. J Clin Oncol. 2019;37(4):S487.</citation>
  </reference>
  <reference>
    <citation>Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, Bennouna J, Desrame J, Faroux R, Kirilovsky A, Duval A, Laurent-Puig P, Svrcek M, Hermitte F, Catteau A, Galon J, Emile JF. Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929. Ann Oncol. 2020 Jul 8. pii: S0923-7534(20)39900-2. doi: 10.1016/j.annonc.2020.06.013. [Epub ahead of print]</citation>
    <PMID>32653357</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Qi Li</investigator_full_name>
    <investigator_title>Executive director of cancer center</investigator_title>
  </responsible_party>
  <keyword>Stage II colon cancer</keyword>
  <keyword>Adjuvant Chemotherapy</keyword>
  <keyword>High-Risk factors</keyword>
  <keyword>High-Immunoscore®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

